1 Department of Multidisciplinary Treatment for Gastroenterological Cancer, Kumamoto University Hospital, Kumamoto, Japan ; 2 Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan.
Hepatobiliary Surg Nutr. 2015 Feb;4(1):72-5. doi: 10.3978/j.issn.2304-3881.2014.07.08.
The role of perioperative chemotherapy in the management of initially resectable colorectal liver metastases (CRLM) is still unclear. The EPOC trial [the European Organization for Research and Treatment of Cancer (EORTC) 40983] is an important study that declares perioperative chemotherapy as the standard of care for patients with resectable CRLM, and the strategy is widely accepted in western countries. Compared with surgery alone, perioperative FOLFOX therapy significantly increased progression-free survival (PFS) in eligible patients or those with resected CRLM. Overall survival (OS) data from the EPOC trial were recently published in The Lancet Oncology, 2013. Here, we discussed the findings and recommendations from the EORTC 40983 trial.
围手术期化疗在可切除结直肠肝转移（CRLM）患者中的作用仍不明确。EPOC 试验[欧洲癌症研究与治疗组织（EORTC）40983]是一项重要的研究，该试验将围手术期化疗作为可切除 CRLM 患者的标准治疗方案，这一策略在西方国家得到广泛认可。与单纯手术相比，围手术期 FOLFOX 治疗可显著延长适合或切除 CRLM 患者的无进展生存期（PFS）。EPOC 试验的总生存（OS）数据最近发表于《柳叶刀肿瘤学》，2013 年。在此，我们对 EORTC 40983 试验的研究结果和建议进行了讨论。
